A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma

References

• Coiffier B. Treatment paradigms in aggressive non-Hodgkin's lymphoma in elderly patients. Clin Lymphoma 2002; 3(Suppl 1)S12–S18
   Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303–307
   PubMed Web of Science ®Google Scholar
• Haddy T B, Adde M A, McCalla J, Domanski M J, Datiles M, III, Meehan S C, et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 1998; 16: 2070–2079
   PubMed Web of Science ®Google Scholar
• Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 277–281
   PubMed Web of Science ®Google Scholar
• Felker G M, Thompson R E, Hare J M, Hruban R H, Clemetson D E, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077–1084
   PubMed Web of Science ®Google Scholar
• Shan K, Lincoff A M, Young J B. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47–58
   PubMed Web of Science ®Google Scholar
• Swain S M, Whaley F S, Ewer M S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–2879
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt W P, Kuse R, Schmitz N. Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity. Br J Haematol 2002; 119: 634–639
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao C S, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444–1454
   PubMed Web of Science ®Google Scholar
• Allen T M. Liposomes. Opportunities in drug delivery. Drugs 1997; 54(Suppl 4)8–14
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419–436
   PubMed Web of Science ®Google Scholar
• Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711–716
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25–36
   PubMed Web of Science ®Google Scholar
• Northfelt D W, Dezube B J, Thommes J A, Miller B J, Fischl M A, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445–2451
   PubMed Web of Science ®Google Scholar
• Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8(Suppl 2)17–24
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Castaneda C, Talavera A, Huerta-Guzman J, Gonzalez M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol 2002; 19: 55–58
   PubMed Web of Science ®Google Scholar
• Di Bella N J, Khan M M, Dakhil S R, Logie K W, Marsland T A, et al. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study. Clin Lymphoma 2003; 3: 235–240
   PubMedGoogle Scholar
• Hussein M A, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95: 2160–2168
   PubMed Web of Science ®Google Scholar
• Wollina U, Dummer R, Brockmeyer N H, Konrad H, Busch J O, Kaatz M, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98: 993–1001
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia F, Jeffers S, Tsao-Wei D D, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029–1033
   PubMed Web of Science ®Google Scholar
• Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing N I, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037–1047
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
   PubMed Web of Science ®Google Scholar
• Verstappen C C, Koeppen S, Heimans J J, Huijgens P C, Scheulen M E, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64: 1076–1077
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Martino R, Perea G, Caballero M D, Mateos M V, Ribera J M, de Oteyza J P, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002; 87: 822–827
   PubMed Web of Science ®Google Scholar
• Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari A L, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47: 2174–2180
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M, Giannouli S, Siakantaris M P, Vassilakopoulos T, et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res 2002; 22: 1845–1848
   PubMed Web of Science ®Google Scholar
• Muggia F M. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997; 54(Suppl 4)22–29
   PubMed Web of Science ®Google Scholar
• Ranson M R, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185–3191
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–1785
   PubMed Web of Science ®Google Scholar
• Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14: 259–264
   PubMed Web of Science ®Google Scholar